Bupivacaine Noridem
Bupivacaine Hydrochloride (Anhydrous) – Long-Acting Local Anesthetic
Bupivacaine Noridem is a long-acting local anesthetic belonging to the amide class. It is administered by injection to numb specific areas of the body during surgical procedures, to relieve pain during labor and delivery, and to manage acute pain in both adults and children. This medication is available only by prescription and must be administered by a qualified healthcare professional with access to resuscitation equipment.
Quick Facts
Key Takeaways
- Bupivacaine Noridem is a long-acting amide local anesthetic used for regional and epidural anesthesia, peripheral nerve blocks, and pain management during and after surgery.
- It must only be administered by or under the supervision of an experienced clinician with immediate access to resuscitation equipment.
- The most common side effects are low blood pressure and nausea; serious but rare complications include cardiac arrhythmias and systemic toxicity from accidental intravascular injection.
- It is widely used for labor epidural analgesia and postoperative pain control, with a duration of action typically ranging from 2 to 9 hours depending on the technique used.
- Tell your doctor about all medications you are taking, especially antiarrhythmic drugs (lidocaine, amiodarone) and blood-thinning medications, as these may interact with bupivacaine.
What Is Bupivacaine Noridem and What Is It Used For?
Bupivacaine Noridem contains the active substance bupivacaine hydrochloride (anhydrous), a well-established local anesthetic that has been in clinical use since the 1960s. It belongs to a group of medicines known as amide-type local anesthetics, which work by reversibly blocking sodium channels in nerve cell membranes. This prevents the generation and conduction of nerve impulses, effectively producing a loss of sensation in the area where the drug is applied.
The mechanism of action involves the drug diffusing through the nerve sheath and binding to sodium channels in the inactive state. By stabilizing the sodium channel in its closed configuration, bupivacaine prevents the rapid depolarization needed for action potential generation. This results in a progressive blockade of sensory, motor, and autonomic nerve function, with sensory fibers typically blocked before motor fibers due to their smaller diameter.
Bupivacaine is distinguished from other local anesthetics by its particularly long duration of action, which makes it especially useful for surgical procedures, postoperative pain management, and labor analgesia. Compared to lidocaine, bupivacaine provides anesthesia lasting approximately 2 to 4 times longer, though its onset of action is somewhat slower. The drug is available in concentrations of 2.5 mg/ml and 5 mg/ml, allowing clinicians to tailor the degree of sensory and motor blockade to the specific clinical situation.
Clinically, Bupivacaine Noridem is indicated for several distinct uses:
- Surgical anesthesia: Numbing parts of the body during operations in adults and children aged 12 years and older, through techniques such as peripheral nerve blocks, epidural anesthesia, and local infiltration.
- Labor analgesia: Providing pain relief during childbirth through epidural or caudal administration, which is one of the most common applications of bupivacaine worldwide.
- Acute pain management: Relieving pain in adults, infants, and children from 1 year of age, including postoperative pain control through continuous epidural infusion or peripheral nerve catheter techniques.
The routes of administration include percutaneous infiltration (injection into the tissues around the surgical site), intra-articular injection (into a joint space), peripheral nerve blockade (injection around specific nerves), and central neuraxial blockade including epidural and caudal techniques. The choice of technique, concentration, and volume depends on the specific clinical indication, the area to be anesthetized, the desired depth and duration of blockade, and individual patient characteristics.
Bupivacaine is included on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its critical role in global healthcare. It remains one of the most widely used local anesthetics in clinical practice worldwide, valued for its favorable pharmacological profile combining potency, long duration, and differential sensory-motor blockade at lower concentrations.
What Should You Know Before Receiving Bupivacaine Noridem?
Bupivacaine Noridem is a powerful local anesthetic that requires careful patient assessment before administration. Your healthcare provider will evaluate your overall health status, current medications, and medical history to determine whether bupivacaine is appropriate for you and to calculate the correct dose. Understanding the contraindications and precautions is essential for safe use of this medication.
Contraindications
Bupivacaine Noridem must not be given in the following situations:
- Allergy to bupivacaine or any excipient: If you have ever had an allergic reaction to bupivacaine hydrochloride or any of the other ingredients in this medicine (sodium chloride, sodium hydroxide, hydrochloric acid, water for injections).
- Allergy to other amide-type local anesthetics: Such as lidocaine, ropivacaine, mepivacaine, or prilocaine. Cross-sensitivity between amide-type agents can occur.
- Skin infection at the injection site: Active infection near the planned injection area, which could spread the infection deeper into the tissues or into the bloodstream.
- Cardiogenic shock: A condition in which the heart cannot pump enough blood to meet the body’s needs, as bupivacaine’s cardiovascular effects could worsen this condition.
- Hypovolemic shock: Severely reduced blood volume leading to circulatory collapse, where regional anesthesia may cause dangerous further drops in blood pressure.
- Coagulation disorders or anticoagulant therapy: Blood clotting problems or concurrent treatment with blood-thinning medications, particularly for neuraxial (epidural/spinal) techniques due to the risk of epidural hematoma.
- Central nervous system diseases: Including meningitis, poliomyelitis, spondylitis, or spinal cord conditions caused by tuberculosis, tumors, or recent injury.
- Intracranial hemorrhage: Severe headache resulting from bleeding within the brain.
- Septicemia: Blood poisoning (systemic infection) which could be worsened by local anesthetic administration.
- Obstetric paracervical block: This specific type of nerve block during labor is contraindicated with bupivacaine due to the risk of fetal bradycardia (slow heart rate in the unborn baby).
Warnings and Precautions
Speak to your doctor or nurse before receiving Bupivacaine Noridem if any of the following apply to you:
- Heart, kidney, or liver problems: These conditions may affect how your body processes bupivacaine, potentially requiring dose adjustments. Patients with hepatic impairment are at increased risk of toxicity because bupivacaine is metabolized primarily in the liver.
- Abdominal swelling due to excess fluid (ascites): May alter the distribution and spread of locally administered anesthetics.
- Abdominal tumors: Can affect drug distribution during epidural or spinal anesthesia.
- Reduced blood volume (hypovolemia): Patients should be adequately hydrated before receiving regional anesthesia to minimize the risk of severe hypotension.
- Fluid in the lungs (pleural effusion): May affect respiratory function during regional anesthesia.
- Epilepsy: Bupivacaine can lower the seizure threshold, potentially triggering convulsions at lower than expected blood concentrations in patients with a history of epilepsy.
- Areas with end-arterial blood supply: Use in areas with arteries that have no alternative blood supply (such as fingers, toes, ear, nose, or penis) requires particular caution, especially if adrenaline (epinephrine) is also used.
Bupivacaine Noridem must only be administered by or under the direct supervision of clinicians experienced in regional anesthesia techniques. Appropriate resuscitation equipment and medications, including intravenous lipid emulsion for treating local anesthetic systemic toxicity (LAST), must be immediately available whenever bupivacaine is used.
Use in Children
The use of Bupivacaine Noridem for surgical anesthesia has not been fully established in children between 1 and 12 years of age. For children in this age group, it is primarily used for pain relief (analgesia) rather than surgical anesthesia. The safety and effectiveness of Bupivacaine Noridem have not been established in infants under 1 year of age. In pediatric patients, doses must be carefully calculated based on body weight, and the lowest effective dose should always be used.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctor before receiving this medicine.
Pregnancy: There is limited data on the use of bupivacaine during early pregnancy. However, bupivacaine is one of the most commonly used local anesthetics for epidural pain relief during labor and delivery worldwide. When used for obstetric analgesia, it has a well-established safety profile at the recommended doses. Paracervical block is specifically contraindicated because of the risk of fetal bradycardia.
Breastfeeding: Bupivacaine passes into breast milk in small amounts. At therapeutic doses, the amount transferred is generally considered to be negligible and unlikely to affect the nursing infant. However, you should discuss the risks and benefits with your doctor if you are breastfeeding.
Fertility: There is no human data on the effect of bupivacaine on fertility. Animal studies have not shown direct adverse effects on reproductive function.
Driving and Operating Machinery
Bupivacaine Noridem may cause drowsiness and affect your reaction time, depending on the dose administered and the type of regional anesthetic technique used. After receiving bupivacaine, you should not drive a car or operate tools or machinery until the following day, as residual effects may persist. Your clinician will advise you on when it is safe to resume these activities based on your individual circumstances.
Sodium Content
This medicine contains sodium. The 5 ml ampoules contain less than 1 mmol (23 mg) of sodium per ampoule and are essentially sodium-free. The 10 ml and 20 ml ampoules contain 3.31 mg sodium per 1 ml, which is equivalent to 0.17% of the WHO-recommended maximum daily intake of sodium for an adult. This information is relevant for patients on a controlled sodium diet.
How Does Bupivacaine Noridem Interact with Other Drugs?
Drug interactions with bupivacaine can be clinically significant and potentially dangerous. Because bupivacaine affects the cardiovascular system and central nervous system, concurrent use with other drugs that have similar effects can amplify toxicity. Your doctor needs to know about all medications you are taking, including over-the-counter drugs and herbal remedies, to calculate the correct dose and anticipate potential interactions.
Major Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Lidocaine | Additive local anesthetic toxicity; combined doses can exceed safe systemic thresholds | High – total dose of all local anesthetics must be calculated together |
| Mexiletine | Additive cardiac sodium channel blockade; increased risk of conduction abnormalities | High – may potentiate cardiotoxicity |
| Amiodarone | Combined cardiac depressant effects; may prolong QT interval and depress myocardial function | High – close cardiac monitoring required |
| Anticoagulants (warfarin, heparin, DOACs) | Increased risk of bleeding complications during regional anesthesia, particularly epidural/spinal hematoma | High – timing of regional anesthesia must be coordinated with anticoagulant therapy |
| Antiplatelet agents (aspirin, clopidogrel) | Increased bleeding risk during neuraxial techniques | Moderate – follow ASRA/ESRA guidelines for timing |
Additional Considerations
Other drugs that may interact with bupivacaine or require special consideration include:
- Other local anesthetics: The toxic effects of local anesthetics are additive. When bupivacaine is combined with any other local anesthetic, the total dose administered must not exceed the maximum safe dose for any single agent.
- Beta-blockers and calcium channel blockers: These cardiovascular medications may enhance the cardiodepressant effects of bupivacaine, potentially leading to greater hypotension and bradycardia.
- CYP3A4 inhibitors: Bupivacaine is metabolized by cytochrome P450 3A4 (CYP3A4). Drugs that inhibit this enzyme (such as ketoconazole, itraconazole, and some HIV protease inhibitors) may increase plasma levels of bupivacaine, potentially raising the risk of toxicity.
- Vasopressors (epinephrine/adrenaline): Often deliberately added to bupivacaine solutions to prolong the duration of action and reduce systemic absorption. However, use of adrenaline-containing solutions in areas with end-arterial blood supply is contraindicated.
Always tell your healthcare provider about every medication you are currently taking, including prescription medicines, over-the-counter products, vitamins, and herbal supplements. This information is essential for calculating the safe dose of bupivacaine and timing its administration appropriately.
What Is the Correct Dosage of Bupivacaine Noridem?
Bupivacaine Noridem is always administered by a healthcare professional experienced in regional anesthesia techniques. The dose is individualized based on the specific procedure, the area of the body to be anesthetized, the degree of blockade required, the patient’s age, body weight, physical condition, and the presence of any underlying medical conditions. The fundamental principle is to use the lowest dose that produces adequate anesthesia or analgesia.
Adults
| Technique | Concentration | Typical Volume | Typical Dose |
|---|---|---|---|
| Local infiltration | 2.5 mg/ml | Up to 60 ml | Up to 150 mg |
| Peripheral nerve block | 2.5–5 mg/ml | 5–40 ml | 12.5–150 mg |
| Epidural (lumbar) | 2.5–5 mg/ml | 10–20 ml | 25–100 mg |
| Epidural (labor analgesia) | 1.25–2.5 mg/ml | 6–15 ml | 7.5–37.5 mg |
| Caudal block | 2.5–5 mg/ml | 15–30 ml | 37.5–150 mg |
Maximum Dose Limits – Adults
- Maximum single dose: 150 mg (without adrenaline)
- Maximum dose over 24 hours: 400 mg (not including the initial bolus dose)
- The lowest dose that provides adequate anesthesia should always be used
Children
In pediatric patients, dosing is weight-based. For pain relief in children aged 1 year and older, the dose is calculated according to the child’s body weight and the specific technique used. The use of bupivacaine for surgical anesthesia has not been fully established in children between 1 and 12 years of age. Pediatric epidural infusions typically use concentrations of 1.25 mg/ml at rates determined by the child’s weight. Safety and efficacy in infants under 1 year have not been established.
When used for caudal epidural block in children aged 1–12 years, the recommended concentration is 2.5 mg/ml. The volume is calculated based on the desired dermatomal level: typically 0.5–1 ml/kg body weight. The maximum recommended dose for pediatric patients should not exceed 2 mg/kg body weight for a single injection.
Elderly Patients
Elderly patients may require reduced doses of bupivacaine. Age-related physiological changes including reduced hepatic blood flow, decreased plasma protein binding, and increased sensitivity to local anesthetics mean that lower concentrations or volumes may provide adequate anesthesia. The onset of action may also be faster, and the duration of blockade may be prolonged in elderly patients. Careful titration and close monitoring are recommended.
Overdose
Overdose with bupivacaine is a medical emergency. While it is unlikely to occur when the drug is administered by an experienced clinician, accidental intravascular injection or administration of an excessive dose can lead to systemic toxicity. The earliest signs of bupivacaine toxicity are typically:
- Dizziness or lightheadedness
- Numbness of the lips and around the mouth
- Numbness of the tongue
- Hearing problems (tinnitus)
- Visual disturbances (blurred vision)
If these warning signs appear, the administration of bupivacaine must be stopped immediately. More serious effects of overdose can include muscle twitching, seizures, loss of consciousness, respiratory arrest, and cardiac arrest. Bupivacaine is particularly associated with cardiovascular toxicity due to its high affinity for cardiac sodium channels, which can lead to refractory ventricular arrhythmias that are notoriously difficult to treat.
Treatment of severe local anesthetic systemic toxicity (LAST) includes airway management, seizure control with benzodiazepines, and intravenous lipid emulsion (ILE) therapy. The Association of Anaesthetists of Great Britain and Ireland (AAGBI), the American Society of Regional Anesthesia (ASRA), and the European Society of Regional Anaesthesia (ESRA) all recommend that 20% lipid emulsion be immediately available wherever local anesthetics are used. The recommended initial bolus dose of 20% Intralipid is 1.5 ml/kg given over 1 minute, followed by a continuous infusion.
If you experience sudden dizziness, ringing in your ears, metallic taste in your mouth, tingling around your lips, visual disturbances, or difficulty speaking during or shortly after receiving bupivacaine, tell your healthcare provider immediately. These may be early signs of systemic toxicity that require urgent treatment.
What Are the Side Effects of Bupivacaine Noridem?
Like all medicines, Bupivacaine Noridem can cause side effects, although not everyone experiences them. Many side effects are directly related to the regional anesthesia technique used rather than the drug itself, and most are transient, resolving as the medication wears off. The frequency and severity of side effects depend on the dose, site of injection, and individual patient factors.
Rare (may affect up to 1 in 1,000 people): Sudden swelling of the face, lips, tongue, or throat; severe difficulty breathing; widespread itching with raised bumps on the skin. These are signs of a serious allergic reaction that requires emergency treatment.
Very Common
May affect more than 1 in 10 people
- Low blood pressure (hypotension) – may cause dizziness or lightheadedness
- Nausea
Common
May affect up to 1 in 10 people
- Vomiting
- Dizziness
- Tingling and numbness (paraesthesia)
- High blood pressure (hypertension)
- Slow heart rate (bradycardia)
- Difficulty urinating (urinary retention)
Uncommon
May affect up to 1 in 100 people
- Unsteadiness
- Seizures (convulsions)
- Numbness of the tongue or around the mouth
- Ringing in the ears (tinnitus) or sound sensitivity
- Speech difficulties
- Blurred vision
- Loss of consciousness
- Tremor (shaking)
- Muscle twitching
Rare
May affect up to 1 in 1,000 people
- Double vision (diplopia)
- Nerve damage (neuropathy) – may cause changes in sensation or muscle weakness, including peripheral neuropathy
- Arachnoiditis – inflammation of the membrane surrounding the spinal cord, causing burning pain in the lower back or legs
- Weak or paralyzed legs
- Irregular heart rhythm (arrhythmia) – potentially life-threatening
- Slowed breathing, respiratory arrest, or cardiac arrest – potentially life-threatening
- Severe allergic reactions (anaphylaxis)
Additional Side Effects Seen with Local Anesthetics
Other side effects that have been observed with local anesthetics in the same class and may also occur with Bupivacaine Noridem include:
- Liver enzyme changes: May occur with prolonged treatment. These are usually transient and clinically insignificant, but liver function should be monitored during extended epidural infusions.
- Nerve damage: In rare cases, this may become permanent. The risk is influenced by needle trauma, intraneural injection, local ischemia, and pre-existing neurological conditions. The incidence of persistent neurological injury from peripheral nerve blocks is estimated at 0.02–0.04%.
- Eye-related complications: Transient blindness or prolonged problems with eye muscles have been reported with certain injection techniques near the eye (retrobulbar/peribulbar blocks). These are technique-specific complications related to the proximity of the injection to orbital structures.
- Post-dural puncture headache: If the dura (the membrane surrounding the spinal cord) is accidentally punctured during an epidural, a positional headache may develop. This is a complication of the technique rather than the drug itself.
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed here. You can also report side effects directly to your national medicines regulatory authority. By reporting side effects, you can help provide more information on the safety of this medicine.
How Should Bupivacaine Noridem Be Stored?
Bupivacaine Noridem is typically stored and handled by healthcare professionals in hospital or clinical settings. However, understanding proper storage conditions is important for ensuring the quality and safety of the medication.
- Temperature: Store protected from cold. Do not freeze. Freezing can damage the polypropylene ampoules and alter the solution.
- Light: No special light protection requirements, but store in the original packaging until use.
- Expiry date: Do not use after the expiry date printed on the ampoule and carton (after EXP). The expiry date refers to the last day of that month.
- Visual inspection: Do not use if the solution is discolored in any way or if particles are visible. The solution should be clear and colorless.
- After opening: For single use only. Use immediately after opening. Discard any unused solution.
- Metal contact: Do not store in contact with metals such as needles or syringes with metal components, as metal ions can precipitate and cause swelling at the injection site.
After Dilution
When Bupivacaine Noridem is diluted (for example, to prepare a 1.25 mg/ml concentration for labor epidural infusions), the chemical and physical stability of the diluted solution has been demonstrated for up to 7 days at room temperature (25 ± 2°C) and up to 24 hours when refrigerated at 2–8°C. From a microbiological standpoint, the product should be used immediately after dilution. If not used immediately, storage should not exceed 24 hours at 2–8°C, unless the opening and dilution were performed under controlled and validated aseptic conditions.
Compatible diluents include 0.9% sodium chloride solution (normal saline) and Ringer’s lactate solution. Bupivacaine Noridem must not be mixed with other medications.
Keep this medicine out of the sight and reach of children. Your healthcare provider or hospital pharmacy is responsible for the proper storage and disposal of this medication. Unused product and waste material should be disposed of in accordance with local requirements.
What Does Bupivacaine Noridem Contain?
Active Substance
The active substance is bupivacaine hydrochloride (anhydrous).
- Bupivacaine Noridem 2.5 mg/ml: Each ml contains 2.5 mg of anhydrous bupivacaine hydrochloride.
- Bupivacaine Noridem 5 mg/ml: Each ml contains 5 mg of anhydrous bupivacaine hydrochloride.
Other Ingredients (Excipients)
- Water for injections (solvent)
- Sodium chloride (for isotonicity adjustment)
- Sodium hydroxide (for pH adjustment)
- Hydrochloric acid (for pH adjustment)
The solution does not contain preservatives, antimicrobial agents, or antioxidants. It is preservative-free, which is essential for neuraxial (epidural and spinal) administration where preservatives could cause neurotoxicity.
Sodium Content
This information is relevant for patients on a sodium-restricted diet:
- 5 ml ampoules: Contain less than 1 mmol (23 mg) of sodium per ampoule, and are essentially sodium-free.
- 10 ml and 20 ml ampoules: Contain 3.31 mg sodium per 1 ml, equivalent to 0.17% of the WHO-recommended maximum daily intake of sodium for an adult.
Appearance and Packaging
Bupivacaine Noridem is a clear, colorless, sterile solution for injection. It is supplied in polypropylene ampoules available in 5 ml, 10 ml, and 20 ml sizes. Ampoules are packed in cartons of 5, 10, or 50 ampoules. Some presentations include individual polypropylene blister packaging for added sterility protection. Not all pack sizes may be marketed in all countries.
Manufacturer and Marketing Authorization
Bupivacaine Noridem is manufactured by DEMO S.A. Pharmaceutical Industry (Athens, Greece) and marketed by Noridem Enterprises Ltd (Nicosia, Cyprus). The product is authorized throughout the European Economic Area under various brand names, including Bupivacaine Noridem in Scandinavian and Central European countries. It is also available under the brand name AMIBUSIN in Greece and Cyprus, and as a generic in the United Kingdom.
Frequently Asked Questions About Bupivacaine Noridem
Bupivacaine Noridem is a long-acting local anesthetic used to numb specific areas of the body during surgical procedures in adults and children over 12, to relieve pain during labor and delivery (epidural analgesia), and to provide acute pain relief in adults, infants, and children from 1 year of age. It is administered by injection using various techniques including local infiltration, peripheral nerve block, epidural, and caudal block.
The duration of action depends on the technique, concentration, and individual patient factors. In general, bupivacaine provides anesthesia for approximately 2 to 9 hours. Epidural analgesia for labor typically lasts 1.5 to 3 hours per bolus dose, while peripheral nerve blocks can last 4 to 12 hours. This long duration is one of bupivacaine’s key advantages over shorter-acting local anesthetics like lidocaine.
Both are amide-type local anesthetics, but they differ in important ways. Bupivacaine has a significantly longer duration of action (2–9 hours vs. 0.5–2 hours for lidocaine), making it better suited for surgical procedures and postoperative pain management. Lidocaine has a faster onset of action and is often used for shorter procedures or as an initial local anesthetic before bupivacaine takes effect. Bupivacaine has greater cardiotoxicity than lidocaine, which is an important safety consideration.
Bupivacaine is one of the most widely used local anesthetics for epidural analgesia during labor and delivery. At recommended doses, it has a well-established safety profile for obstetric use. However, paracervical block is specifically contraindicated due to the risk of fetal bradycardia. Bupivacaine passes into breast milk in small amounts, but the quantity is generally considered negligible and unlikely to affect the nursing infant. Always discuss your situation with your doctor.
Early signs of systemic toxicity include dizziness, lightheadedness, numbness of the lips, tongue, and mouth area, ringing in the ears, blurred vision, and metallic taste. If left untreated, these can progress to muscle twitching, seizures, loss of consciousness, and potentially cardiac arrhythmias, respiratory arrest, or cardiac arrest. Bupivacaine is particularly associated with cardiovascular toxicity. If you notice any of these symptoms during or after receiving bupivacaine, alert your healthcare provider immediately.
Tell your doctor if you have heart, kidney, or liver problems; if you are taking blood-thinning medications (anticoagulants) or heart rhythm medications (antiarrhythmics); if you have epilepsy; if you have reduced blood volume; or if you are allergic to any amide-type local anesthetics. Also inform your doctor if you are pregnant, breastfeeding, or planning to become pregnant. These factors can affect whether bupivacaine is safe for you or require adjustments to the dose.
References
This article is based on the following evidence-based sources:
- European Medicines Agency (EMA). Bupivacaine – Summary of Product Characteristics. EMA Product Database. Available at: www.ema.europa.eu
- World Health Organization. WHO Model List of Essential Medicines – 23rd Edition (2023). Bupivacaine listed as essential local anesthetic. Available at: www.who.int
- Neal JM, Barrington MJ, Fettiplace MR, et al. The Third American Society of Regional Anesthesia and Pain Medicine Practice Advisory on Local Anesthetic Systemic Toxicity. Regional Anesthesia & Pain Medicine. 2018;43(2):113-123. doi:10.1097/AAP.0000000000000720
- European Society of Regional Anaesthesia and Pain Therapy (ESRA). Guidelines on Neuraxial Anesthesia and Anticoagulation. Regional Anesthesia & Pain Medicine. 2023.
- Berde CB, Strichartz GR. Local Anesthetics. In: Miller RD, ed. Miller’s Anesthesia. 9th ed. Elsevier; 2020:868-914.
- British National Formulary (BNF). Bupivacaine Hydrochloride. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk
- Food and Drug Administration (FDA). Bupivacaine Hydrochloride Injection – Prescribing Information. Available at: www.fda.gov
- El-Boghdadly K, Pawa A, Chin KJ. Local anesthetic systemic toxicity: current perspectives. Local and Regional Anesthesia. 2018;11:35-44. doi:10.2147/LRA.S154512
Editorial Team
iMedic Medical Review Board – Independent panel of medical experts specializing in anesthesiology, clinical pharmacology, and pain medicine. All content reviewed according to international guidelines (WHO, EMA, FDA, ESRA, ASRA).
Evidence Level 1A based on systematic reviews and randomized controlled trials. GRADE evidence framework applied. No commercial funding or pharmaceutical industry sponsorship.
Last medical review: | Published: